Search
  • Search


Ireland: Tenders/Health Service Executive (HSE)/National Contract for Monoclonal Antibody for Respiratory Syncytial Virus (RSV) Passive Immunisation for Infants - Pathfinder Programme 3
  1. Questions deadline

    Jan 13, 11:00 AMJanuary 13, 2026 11:00 AM
  2. Tender submission deadline

    Jan 20, 11:00 AMJanuary 20, 2026 11:00 AM
  3. Tender validity period

    Apr 20, 10:00 AMApril 20, 2026 10:00 AM
  4. Result notice published

    Sep 30, 9:11 AMSeptember 30, 2026 9:11 AM

Brief

National Contract for Monoclonal Antibody for Respiratory Syncytial Virus (RSV) Passive Immunisation for Infants - Pathfinder Programme 3

Awarded

The competition has ended and a winner has been selected.

Procedure
Without prior noticeTwo stages
Agreement
Buying goods
Estimated value
€1

Brief

The Health Service Executive (HSE) has entered into an agreement with Sanofi for the delivery of 50,000 doses of the monoclonal antibody Nirsevimab (Beyfortus®) for passive immunisation against Respiratory Syncytial Virus (RSV) in infants. This contract, valued at 1 EUR, is for a third pathfinder immunisation programme to protect babies born from March 1, 2026, to February 28, 2027, with delivery occurring in Dublin over a seven-month period during the RSV season. The purpose is to protect all babies from RSV disease, which commonly causes respiratory infections and can lead to hospitalisation in young infants.

Farmasøytisk engroshandel

Result

TED
  • Sanofi
    Winner
  • Number of tenders received
    1
  • Contract value
    €1

Custom Assessment Criteria

  • Get answers to your bid/no-bid criteria

    Set them up once and Cobrief answers them in every tender

Will you bid?

The agent sets up the bid and writes the first draft. Free for 14 days.

Award Criteria

  • Description

    Negotiated

    Source

    No source found in the documents. Check the weight against the tender documents.

  • Description

    Negotiated with sole authorised supplier

    Source

    No source found in the documents. Check the weight against the tender documents.

Previous winners

  • Who are you up against?

    The suppliers who have won similar contracts at Health Service Executive (HSE)

From the notice

  • In accordance with National Immunisation Advisory Committee (NIAC) advice, HSE Public Health: National Health Protection, with Access & Integration and the National Women and Infants Health Programme wish to put in place a contract for a monoclonal antibody, Nirsevimab (Beyfontus®) for a third pathfinder immunisation programme to protect all babies from RSV disease born from 1st March 2026 to 28th February 2027. RSV is a common virus that causes respiratory infections in young babies. Babies under three months old get sicker with RSV than older children. Each winter in Ireland one in two newborns babies will get RSV and many will need medical care from their GP or the emergency department of a children’s hospital. Four out of a hundred new born babies are hospitalised due to RSV with some babies needing special treatment in intensive care units. Nirsevimab is currently the best way to protect babies from RSV. This contract will supply 50,000 doses of this drug for passive immunisation over a seven month period during the RSV season.

  • Contact

    procurement.helpdesk@hse.ie
  • Type
    Result · Prequalification
  • Location
    Dublin
  • Main code
    Vaccines
    33651600

Similar active competitions

  • Sykehusinnkjøp Hf

    Farmasøytisk engroshandel

    Veiledende kunngjøring: 2772 RSV-beskyttelse barnevaksinasjonsprogram

    Sykehusinnkjøp HF skal på vegne av Direktoratet for medisinske produkter, i samarbeid med Folkehelseinstituttet og Helsedirektoratet, anskaffe et produkt til forebyggende behandling mot RSV i barnevaksinasjonsprogrammet. Den maksimale samlede kontraktsverdien er 945 millioner kroner, og anskaffelsen er forbeholdt bevilgning over statsbudsjettet.

    Planning
    Feb 28, 2027(101 days)
    NOK 945,000,000
  • Children's Health Ireland (CHI)

    Engroshandel med medisinske og husholdningsvarer

    Design and Supply of Newborn Screening Cards for the Collection of Blood Samples for the National Newborn Screening Programme

    Children’s Health Ireland (CHI) needs the design and supply of newborn screening cards for the National Newborn Screening Programme under a 5-year supply contract, with a stated maximum total value of €1. The cards must use suitable filter paper to collect heel-prick blood samples from infants, accommodate metabolites currently analysed and future additions, and provide space for full infant demographics and other programme-required details. Delivery is in Dublin.

    Competition
    Dec 10, 2026(21 days)
    €1
  • Health Service Executive (HSE)

    Medisinsk og laboratorieutstyr

    HSE 28180 Dynamic Purchasing System (DPS) Invitation for the Supply of Infusion Consumable Products

    Health Service Executive (HSE) needs infusion consumable products for a maximum total value of 25,000,000 EUR. This DPS is for the supply of infusion consumable products, excluding NRFit Consumable Products or IV Equipment, Accessories, and dedicated Consumables.

    Dynamic purchasing system
    Feb 12, 2031(100+ days)
    €25,000,000